Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

615.O1.8 Acute Myeloid Leukemia - Therapy, Excluding Transplantation

Monday, December 8, 2008: 7:00 AM-9:00 AM
Yerba Buena Ballroom Salon 7 (San Francisco Marriott)
Moderators:
Deborah Mulford, MD and Pierre Fenaux
7:00 AM
Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients

Jerzy Holowiecki1, Sebastian Grosicki1*, Slawomira Kyrcz-Krzemien1*, Kazimierz Kuliczkowski2*, Aleksander B. Skotnicki3*, Andrzej Hellmann, MD, PhD4*, Tadeusz Robak, MD, PhD5, Kazimierz Sulek6*, Anna Dmoszynska7, Janusz Kloczko8*, Wieslaw Wiktor Jedrzejczak9*, Barbara Zdziarska10*, Krzysztof Warzocha11*, Krystyna Zawilska12*, Marek Kielbinski2*, Beata Piatkowska-Jakubas3*, Agnieszka Wierzbowska5*, Olga Haus13*, Beata Stella-Holowiecka1*, Malgorzata Krawczyk-Kulis1*, Malgorzata Wach7* and Anna Ejduk11*

1Dept. of Hematology and BMT, Silesian Medical University Hospital SPSKM, Katowice, Poland
2Dep.of Hematology, Wroclaw Medical University, Wroclaw, Poland
3Collegium Medicum, Uniwersytetu Jagielonskiego, Krakow, Poland
4Department of Hematology, Medical University of Gdansk, Gdansk, Poland
5Department of Hematology, Medical University of Lodz, Lodz, Poland
6Dept. of Clinical Hematology, Military Medical Institute, Warsaw, Poland
7Hematooncology, Medical University of Lublin, Lublin, Poland
8Dept. of Hematology, Bialystok Medical Academy, Bialystok, Poland
9Department of Hematology and Oncology, Medical University, Warsaw, Poland
10Dept. of Clinical Hematology, Pomeranian Medical University, Szczecin, Poland
11Institute of Hematology and Blood Transfusion, Warsaw, Poland
12Dept. of Internal Medicine, Strus Hospital, Poznan, Poland
13Dept. of Clinical Genetics, Collegium Medicum of Copernicus University, Bydgoszcz, Poland

7:15 AM
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

Roelof Willemze, MD, PhD1, Stefan Suciu2, Franco Mandelli3*, Boris Labar, MD, PhD4, Jean-Pierre Marie5*, Martin Mistrik, MD, PhD6, Vincenzo Liso7*, Francesco Fabbiano8*, Francesco Nobile9*, Marco Sborgia10*, Bruno Rotoli11, Dominik L.D. Selleslag, MD12, Francois Lefrere Sr., MD13*, Antonio Peta14*, Massimo F Martelli15*, Giuseppe Leone16, Nicola Cantore17*, Meral Beksac18*, Zwi Berneman19*, Xavier Thomas20, Michele Mario Greco21*, Dominique Bron22, Georges Fillet23, Jose E. Guimaraes, MD, PhD24, Petra Muus25*, Paola Fazi26*, Liliana Baila27*, Marco Vignetti28*, Sergio Amadori29, Theo de Witte on behalfhe European Group for Blood and Marrow Transplantation25* and Giovanna Meloni3*

1Dept. of Hematology, Leiden Univ. Med. Ctr., Leiden, Netherlands
2EORTC Leukemia Group, Brussels, Belgium
3Universita La Sapienza, Rome, Italy
4Dept. of Medicine, Div. of Hematology, University Hospital Center - Rebro, Zagreb, Croatia
5Hotel Dieu, Paris, France
6Dept. of Hematol. & Transfusiology, Univ. Hosp., Bratislava, Slovak Republic
7Hematology, Università degli Studi di Bari, Bari, Italy
8Ospedale Cervello, Palermo, Italy
9Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
10Ospedale di Pescara, Pescara, Italy
11Dipartimento di Ematologia, Università degli Studi di Napoli, Napoli, Italy
12Az Sint-Jan, Brugge, BEL
13Hematology, Necker Hospital, Paris, France
14Ospedale Regionale A. PUGLIESE, Catanzaro, Italy
15Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
16Istituto di Ematologia, Rome, Italy
17Ospedale Civile AVELLINO, Rome, Italy
18IBNI SINA Hospital, Ankara, Turkey
19Universitair Ziekenhuis, Antwerpen, Belgium
20Hopital Edouard Herriot, Lyon, France
21Hematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
22Dept. of Experimental Hem., Jules Bordet Institute, Brussels, Belgium
23ULg, Liege, Belgium
24Hospital S. Joao, Porto, Portugal
25UMC St Radboud, Nijmegen, Netherlands
26Division of Hematology, Department of Cellular Biotechonologies and Hematology, “La Sapienza” University, Rome, Italy
27EORTC Headquarters, Brussels, Belgium
28Dept of Biotechnologies and Hematology, “La Sapienza” University, Rome, Italy
29Ematologia Tor Vergata, Rome, Italy

7:30 AM
Long-Term Follow-up of the Randomized JALSG AML 201 Study Comparing High Dose Ara-C Therapy with Conventional Consolidation Therapy in Adult Acute Myeloid Leukemia (AML)

Shuichi Miyawaki1, Shigeki Ohtake2, Shin Fujisawa2*, Hitoshi Kiyoi2*, Katsuji Shinagawa2*, Noriko Usui2*, Kohichi Miyamura, MD2*, Miki Nishimura, MD2*, Yasushi Miyazaki2*, Kazuhiro Nishii2*, Tadashi Nagai2*, Takahisa Yamane, MD2*, Masafumi Taniwaki2*, Masatomo Takahashi, MD2*, Fumiharu Yagasaki2*, Yukihiko Kimura2*, Norio Asou2*, Sumihisa Honda2*, Kazunori Ohnishi2*, Tomoki Naoe2* and Ryuzo Ohno2*

1Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
2Japan Adult Leukemia Study Group, Japan

7:45 AM
COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Janet Franklin, MD, MPH1*, Todd Alonzo, PhD2, Craig Alan Hurwitz, MD3*, Robert Gerbing4*, Franklin Smith5*, Robert J. Arceci, MD, PhD6, James Feusner, MD7*, Prasad Mathew, MD8, Robert Iannone, MD9, Soheil Meshinchi, MD, PhD10, Robert Lavey, MD, MPH11*, Joetta D Wallace, RN12*, Kelly Anderson, RN13*, Laura Winter, PharmD14*, Kathleen Glick, BA3*, Betty Hirsch, MD15*, Susana C. Raimondi, PhD16 and Alan Gamis, MD17

1Keck School of Medicine, University of Southern California, Los Angeles, CA
2Keck School of Med., Univ. of Southern California, Arcadia, CA
3The Maine Children's Cancer Program, Scarborough, ME
4Children's Oncology Group, Arcadia, CA
5Hematology/Oncology and Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH
6Bunting-Blaustein Cancer Research Building, Sidney Kimmel CCC at Johns Hopkins, Baltimore, MD
7Hematology/Oncology, Children's Hospital Oakland, Oakland, CA
8Univ. of NM Health Science Ctr., Albuquerque, NM
9Children's Hospital of Philadelphia, Narberth, PA
10Clinical Research, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA
11CRO, Brandon, FL
12Miller Children's Hospital, Long Beach, CA
13Oregon Health Science Center, Portland, OR
14Seattle Children's Hospital, Seattle, WA
15University of Minnesota, Minneapolis, MN
16St. Jude Children's Rsch. Hosp., Memphis, TN
17Children's Mercy Hospital, Kansas City, MO

8:00 AM
Treatment with All-Trans Retinoic Acid and Anthracycline Monochemotherapy in Children with Acute Promyelocytic Leukemia: Analysis of Three Sequential Multicenter Trials of the PETHEMA Group

Luis Madero1*, Pau Montesinos, MD2*, Pilar Bastida, MD3*, Amparo Verdeguer, MD4*, Javier De la Serna, MD5*, Antonio Molines, MD6*, Purificacion Garcia, MD7*, Jose Luis Fuster, MD8*, Maria jose Allegue, MD9*, Rafael Rojas, MD10* and Miguel A. Sanz, MD, PhD2

1MD, Nino Jesus Children's Hospital, Madrid, Spain
2On behalf of the PETHEMA, HOVON, PALG, and GATLA cooperative groups, Valencia, Spain
3H. U. Vall dxHebron (infantil), Barcelona
4Hematology, Hospital Universitario La Fe, Valencia, Spain
5Hospital 12 de Octubre, Spain, Spain
6Hospital Materno-Infantil de Las Palmas, Las Palmas, Spain
7Hospital La Paz (infantil), Madrid, Spain
8H. U. Virgen de la Arrixaca (infantil), Murcia, Spain
9Hospital Montecelo, Pontevedra, Spain
10Hospital Reina Sofía, Cordoba, Spain

8:15 AM
Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All-Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients

Miguel A. Sanz, MD, PhD, Pau Montesinos*, Aleksandra Holowiecka*, Gustavo Milone*, Chelo Rayon*, Elena de Lisa*, Javier de la Serna*, Salut Brunet*, Angel Leon*, Isabel Krsnik*, Concha Rivas*, Jose M. Ribera*, Jose Gonzalez*, Joaquín Díaz-Mediavilla*, Javier Bueno*, Jose David Gonzalez*, Juan Bergua* and Marcos Gonzalez*

PETHEMA cooperative group, Valencia, Spain

8:30 AM
Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL

Sylvain Thepot*, Claude Gardin*, Sylvie Chevret*, Stephane de Botton*, Emmanuel Raffoux*, Agnes Guerci*, Xavier Thomas*, Arnaud Pigneux*, Norbert Vey*, Thierry Lamy*, Francoise Huguet*, Anne Vekhoff*, Sandrine Meyer*, Chelo Rayon*, Thomas Pabst*, Patrice Chevalier*, Frederic Maloisel*, Eric Deconinck*, Augustin Ferrant*, Dominique Bron*, Herve Dombret*, Nathalie Fegueux*, Javier de la Serna*, jean-Yves Cahn*, Norbert Ifrah*, Miguel A Sanz*, Pierre Fenaux* and Lionel Ades

European APL group, Bobigny, France

8:45 AM
Treatement of New Cases of Acute Promyelocytic Leukemia by Arsenic Trioxide Whitout ATRA +/- Chemotherapy and Long Term Follow up of Patients

Ardeshir Ghavamzadeh1*, Kamran Alimoghaddam, MD1, Seyed Hamidolah Ghaffari1*, Shahrbano Rostami1*, Mohamad Jahani1*, Rohollah Hosseini2*, Massoud Iravani1*, Seyed Asadollah Mossavi1*, Ali Khodabandeh1*, Babak Bahar1*, Eissa Baybordi1*, Mehrangiz Tootonchi1*, Ezat Eini1*, Zahra Nasri Moghadam1*, Fakhri Afshar1* and Parvin Radsafa1*

1Dept. of Hem., Onc., & BMT, hematology, oncology and stem cell transplantation research center of Tehran university of medical sciences, Tehran, Iran
2Pharmacy Faculty, Tehran university of medical sciences, Tehran, Iran

*signifies non-member of ASH